Bridging Innovation and Reliability: Why Animal Studies Still Matter in the Age of NAMs
Research_Facility
This article was originally published in Pharmaceutical Executive. The landscape of preclinical research is shifting fast—and 2025 may mark a defining moment. In April, the FDA announced its plan to remove the requirement for animal testing of monoclonal antibodies and other drugs, and in July, the National Institutes of Health announced it will no longer fund studies that rely exclusively ... Read More The post Bridging Innovation and Reliability: Why Animal Studies Still Matter in the Age of N